Mike Wilson | May 2025
CAR-T cell therapy is a personalised immunotherapy approach that involves the modification of T cells in a patient's immune system to target and destroy cancer cells. To date, six CAR-T cell therapies have been approved by the United States Food and Drug Administration (FDA) for the treatment of lymphoma, leukaemia and multiple myeloma. However, its application in solid tumours, such as neuroblastoma, remains an area of active research.
A recent case study highlights the potential long-term efficacy of CAR-T cell therapy in treating neuroblastoma. Neuroblastoma is a rare cancer that develops in immature nerve cells, primarily affecting children under the age of five. It is associated with high relapse rates, making long-term remission particularly challenging. The clinical trial evaluating so-called GD2 CAR-T cell therapy enrolled 19 children with neuroblastoma between 2004 and 2009. Between two months and seven years after the therapy, 12 of them passed away due to relapsed neuroblastoma. However, excitingly, one of them has remained in complete remission for over 18 years, the longest recorded case for this treatment. Notably, she has since given birth to two healthy children.
The findings from this study provide valuable insights into the potential of CAR-T cell therapy for solid tumours. Challenges clearly remain: most patients died after all. Future work must focus on improving long-term survival rates and reducing relapse. However, this case highlights the tantalising possibility of durable remission and improved quality of life for patients with neuroblastoma, and perhaps in future also for sufferers of a variety of other solid tumours1.
Mike Wilson
AVP | Medical Analytics
Medical Advances
Pancreatic cancer remains one of the most lethal cancers, even for patients who undergo surgical tumour removal. Could a new personalised vaccine improve outcomes for patients?
Medical Advances
Is there a link between cancer and Alzheimer's? A latest study suggest there is...
Medical Advances
Examining the potential of CAR-T cell therapy for solid tumours
Protection
When asked what opportunities life reinsurers in Asia have, Pacific Life Re's Vasan Errakiah was quick to cite demand for insurance, changing regulations and the adoption of new technologies.
Protection
Asia Insurance Review spoke to Pacific Life Re's Mr Ong Qian Hao and FWD Group's Ms Fiona Hermans to understand how strategic partnerships can effectively address these challenges and lead to successful outcomes.
Medical Advances
Read our update on the impact of mortality from COVID-19.
Medical Advances
Lung cancer is often diagnosed at a late stage leading to poor prognosis for the individual. We look at how screening could have an impact.
Underwriting & Claims
Underwriting has been going through significant transformation over the last few years and continues to accelerate at an unprecedented pace. Traditionally seen as a barrier, there is now a growing opportunity to position underwriting as a strategic asset.
Protection
Big data analytics has been instrumental for (re)insurers aiming to boost performance, efficiency, and effectiveness.
Medical Advances
From emerging drugs which battle obesity to a review of the effectiveness of new blood tests both to detect cancer and to help slow down Alzheimer’s, we hope these insights help keep you up to date with the latest in medical research.
Medical Advances
Vaping is generally considered less harmful than smoking, however longer-term risks have not had time to emerge and could prove considerable.
Medical Advances
Despite broadly improving cancer mortality, some types of the disease are increasing in incidence
Protection
Consumer Duty has put increased focus on how much value different customers get from financial products. But how well is the protection industry serving different customer groups? Who are the most underserved groups, and what can the industry do to help serve these groups better?
Underwriting & Claims
Underwriting processes, practices and philosophies are changing with faster pace than we have ever experienced before.
Medical Advances
A new generation of drugs has now well and truly arrived aiming to improve weight loss. The drugs are heavily touted by celebrities and influencers, despite many of them having no medical need to lose weight. Obesity contributes significantly to some of the most common causes of death including heart disease and cancer, as well as affecting quality of life for millions. In this article we look at these increasingly available drugs offering hope to more people with obesity. We consider their potential to broadly improve health, and their limitations.
Medical Advances
Scientists successfully conducted early-stage trials which provide hope of a future cure for some of the most severe types of multiple sclerosis (MS).
Medical Advances
The world’s largest conference dedicated to the science and treatment of cancer took place in Chicago in early June. The American Society of Clinical Oncology’s annual meeting is a popular forum at which new scientific developments are often revealed.
Medical Advances
A recent review by WHO resulted in reclassification of pituitary adenoma as described in the article
Medical Advances
In 2023 we’ve seen soaring temperatures across the globe along with devastating storms and wildfires. Why is our climate changing and what impact is it having?
Medical Advances
Welcome to our first edition of Vital Insights. Here we’ve put together a collection of articles covering some of the major issues of the day with a specific focus on how they will impact mortality and morbidity.
Medical Advances
Total deaths from dementias in high-income countries have almost quadrupled in the last 20 years, yet so far medical science has very few answers. This article looks at the recent emergence of the first drugs which may be able to modify the effects of this terrifying disease
Medical Advances
COVID-19 has stolen the limelight from other respiratory viruses in recent years. However there are plenty of other common viruses which can have serious health consequences, among them Respiratory Syncytial Virus, or RSV.
Medical Advances
A new UN report reveals optimism about a possible end to the global AIDS epidemic
Medical Advances
Vaccine technologies have continued to improve greatly in recent years. However, vaccines are little use if people refuse to use them. Here we look at the precarious position of measles, a well-known but little-understood serious condition, which is held in check in most countries only because of high vaccine uptake.
Medical Advances
The International Agency for Research on Cancer (IARC), the cancer research arm of the WHO, recently classified the common sweetener aspartame as a possible cause of cancer in humans.
Protection
Beneath the Surface report 2023 We explored some of the key drivers of sustainability for the protection market. We undertook consumer research which combined with our medical and underwriting expertise and our deep understanding of the market, enabled us to create this report.
Protection
Beneath the Surface report 2022 In this report, we analyse the current VAS landscape in the UK & Irish protection markets. Look to understand the views and experiences of customers, with the aim of assessing how much value these services are really adding today. Look at what insurers say, and consider what the future might hold for the development of VAS.